Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-11-08Clinical Trial Update: Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia [Phase 2]
This Phase 2 trial studied venetoclax in combination with the CACAG regimen for newly diagnosed acute myeloid leukemia. The study has comple…
-
CLINICAL_TRIALS research · 2024-11-08Clinical Trial Update: Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax [Phase 2]
A Phase 2 clinical trial is evaluating a decitabine plus venetoclax combination for adults with acute myeloid leukemia arising from myelopro…
-
CLINICAL_TRIALS research · 2024-11-08Clinical Trial Update: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML [Phase 3]
Phase 3 trial evaluating gemtuzumab ozogamicin in combination with chemotherapy to assess minimal residual disease levels in adults with unt…
-
CLINICAL_TRIALS research · 2024-11-08Clinical Trial Update: PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS [Phase 1]
Phase 1 trial update for PRGN-3006 adoptive cellular therapy targeting CD33-positive acute myeloid leukemia, including MRD-positive AML or h…
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission [Phase 2]
Phase 2 trial evaluating PD-1 blockade in combination with a dendritic cell/AML vaccine after chemotherapy-induced remission in acute myeloi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation
The study evaluating venetoclax tablets in adults with acute myeloid leukemia ineligible for standard induction therapy in the Russian Feder…
-
CLINICAL_TRIALS research · 2024-11-07Clinical Trial Update: NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy [Phase 2]
Phase 2 clinical trial update evaluating N-acetylcysteine (NAC) to promote hematopoietic recovery after chemotherapy in Acute Myeloid Leukem…
-
CLINICAL_TRIALS trial_result · 2024-11-06Clinical Trial Update: Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia [Phase 1]
A Phase 1 clinical trial evaluating allogeneic natural killer cell therapy for acute myeloid leukemia has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-11-06Clinical Trial Update: Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
This update reports the completion of a Phase 1 dose-escalation study of ASP2215 (gilteritinib) in Japanese patients with Relapsed or Refrac…
-
CLINICAL_TRIALS trial_result · 2024-11-06Clinical Trial Update: MargheRITA (Remote Intelligence for Therapeutic Adherence) [NA]
A completed clinical trial named MargheRITA (Remote Intelligence for Therapeutic Adherence) sponsored by Advice Pharma Group srl studied tre…
-
CLINICAL_TRIALS trial_result · 2024-11-06Clinical Trial Update: Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease [Phase 1]
Phase 1 trial of natural killer cell therapy for acute myeloid leukemia presenting minimal residual disease has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-11-06Clinical Trial Update: A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia
This clinical trial update describes a post-marketing safety surveillance study evaluating oral azacitidine maintenance therapy in Korean pa…
-
EMA approval · 2024-11-05EMA Authorised: Vidaza (azacitidine) — Bristol-Myers Squibb Pharma EEIG
The EMA authorised Vidaza (azacitidine) in the EU for myelodysplastic syndromes and certain leukemias, including chronic myelomonocytic leuk…
-
CLINICAL_TRIALS trial_result · 2024-11-05Clinical Trial Update: A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 1]
Phase 1 study evaluating ASP2215 (gilteritinib) in combination with induction and consolidation chemotherapy in newly diagnosed acute myeloi…
-
CLINICAL_TRIALS research · 2024-11-05Clinical Trial Update: Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review
This completed retrospective chart review investigated treatment patterns and healthcare resource use in acute myeloid leukemia with or with…
-
CLINICAL_TRIALS research · 2024-11-05Clinical Trial Update: Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML [NA]
This clinical trial update indicates the study is currently RECRUITING to evaluate endothelial dysfunction and myocardial contractility in a…
-
CLINICAL_TRIALS trial_result · 2024-11-04Clinical Trial Update: Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia [Phase 2]
Phase 2 trial testing nivolumab and azacitidine with or without ipilimumab for refractory/relapsed or newly diagnosed acute myeloid leukemia…
-
CLINICAL_TRIALS research · 2024-11-04Clinical Trial Update: Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML [Phase 1, Phase 2]
Clinical trial update on the safety and efficacy of expanded, universal donor natural killer cells for relapsed/refractory acute myeloid leu…
-
CLINICAL_TRIALS trial_result · 2024-11-01Clinical Trial Update: Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
Phase 1 trial evaluating the combination of talazoparib and gemtuzumab ozogamicin for CD33-positive relapsed or refractory acute myeloid leu…
-
CLINICAL_TRIALS trial_result · 2024-11-01Clinical Trial Update: A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) [Phase 1]
A terminated Phase 1 study evaluating safety, tolerability, and pharmacokinetics of escalating doses of AGS67E as monotherapy in adults with…
-
CLINICAL_TRIALS trial_result · 2024-10-30Clinical Trial Update: Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation [Phase 2]
Phase 2 clinical trial update on a Triplex CMV vaccine designed to prevent CMV infection in patients undergoing hematopoietic stem cell tran…
-
CLINICAL_TRIALS trial_result · 2024-10-29Clinical Trial Update: Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm [Phase 2]
Phase 2 evaluation of CPX-351 monotherapy in acute myeloid leukemia secondary to myeloproliferative neoplasm has completed.
-
CLINICAL_TRIALS trial_result · 2024-10-29Clinical Trial Update: Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy [Phase 2]
Clinical trial update on eltrombopag for elderly patients with acute myeloid leukemia undergoing induction chemotherapy (Phase 2).
-
CLINICAL_TRIALS research · 2024-10-29Clinical Trial Update: Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML) [Phase 2]
Phase 2 trial evaluating the addition of dexamethasone to intensive chemotherapy in older patients with acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2024-10-26Clinical Trial Update: Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies [Phase 1]
This Phase 1 trial evaluated the combination of venetoclax and selinexor in relapsed or refractory high-risk hematologic malignancies, inclu…